Market Research Blog – Page 1343 – New Product Development

Orthopedic Braces and Support Market Expected to Grow Significantly, Projected to Reach USD 8.8 Billion by 2034 at a 6.7% of CAGR

The global orthopedic braces and support market is on a robust growth trajectory, with projections indicating a substantial increase from an estimated valuation of USD 4.6 billion in 2024 to USD 8.8 billion by 2034. This growth reflects a commendable compound annual growth rate (CAGR) of 6.7% over the assessment period.

The anticipated market expansion is driven by increasing awareness of orthopedic health, a rising prevalence of musculoskeletal disorders, and advancements in orthopedic technology. These factors are contributing to a heightened demand for orthopedic braces and supports, which play a crucial role in injury prevention, rehabilitation, and management of chronic conditions.

The expanding market is driven by an increasing prevalence of musculoskeletal disorders, a rising aging population, and growing awareness of orthopedic health. Technological advancements in brace and support design, along with a growing focus on preventive care and rehabilitation, are further contributing to market expansion.

The orthopedic braces and support market encompasses a wide range of products designed to assist in the treatment and management of various orthopedic conditions, enhancing mobility and providing support for individuals recovering from injuries or surgeries.

The healthcare industry is embracing technological intervention with digital health, virtual health, and telehealth to treat patients.

Such trends are emerging as a potential disruptor in the orthopedic braces and support market, which has been facing the brunt of the COVID-19 pandemic.

Key Takeaways :

Rising Incidence of Orthopedic Disorders: The prevalence of orthopedic conditions such as osteoarthritis, osteoporosis, and sports injuries is increasing globally, leading to a growing demand for orthopedic braces and support products.
Increasing Awareness and Adoption: There is a growing awareness among patients and healthcare professionals about the benefits of using orthopedic braces and supports for rehabilitation, injury prevention, and pain management, driving the adoption of these products.
Technological Advancements: Advances in materials science and manufacturing technologies are enabling the development of lightweight, ergonomic, and customizable orthopedic braces and support solutions, enhancing patient comfort and compliance.

As the global population continues to age and lifestyles become increasingly sedentary, the demand for orthopedic braces and support products is expected to witness sustained growth in the coming years.

Top Recommended Strategies to Stay Ahead of Market Competition:

Key players can use smart sensors, materials, and biofeedback mechanisms to provide rehabilitation experiences and personalized support for effective rehabilitation bracing solutions.
Companies need to prioritize research to develop new materials, applications, and designs for braces and support to effectively meet the needs of patients and align with emerging trends.
Industry participants can consider collaborating with experts to prepare products validated for science and practical use cases.
Market contenders can offer customization options like personalized support levels and custom-fit braces to meet individual needs effectively.
By focusing on streamlining the purchase process, like offering hassle-free returns and convenient online ordering options, players can build loyalty and trust among their target market.

Recent Developments

In October 2023, OrthoPediatrics Corp. launched the DF2 Brace as a strategy to expand into non-surgical business to treat kids suffering from musculoskeletal injuries.
In September 2023, Enovis Corporation officially disclosed the acquisition of LimaCorporate S.p.A. The acquisition of the latter company added a wide variety of orthopedic medical devices like braces and other support apparatus.

Key Players in the Orthopedic Braces and Support Industry:

DJO, LLC (United States)
Zimmer Biomet (United States
Medtronic (Ireland)
Stryker Corporation (United States)
Össur (Iceland)
NuVasive®, Inc (United States)
Integra LifeSciences Corporation (United States)
Globus Medical (United States)
OTTOBOCK (Germany)
AC Mould Engineering Limited (China)
Johnson and Johnson Services, Inc (United States)
Weber Orthopedic LP. DBA Hely and Webe (United States)
BSN medical (India)
Becker Orthopedic (United States)
OPPO MEDICAL INC (United States)
Langer Biomechanics (United States)
Frank Stubbs Company Inc. (United States)
DeRoyal Industries, Inc (United States)
Ascent Meditech Limited (India)
Alcare Co., Ltd (Tokyo)
Others

Orthopedic Braces and Support Industry by Category:

By Product:

Braces and Supports Type
- Knee Braces for Osteoarthritis and Ligament Injuries
- Post-operational Knee Braces
- Upper Spine Orthoses
- TLSOs
- LSOs
- Soft Braces
- Hinged Braces
- Pneumatic
- Non-pneumatic
- Elbow Braces and Supports
- Wrist Braces and Supports
Pain Management Products
- Cold Therapy Products
- DVT Products

By End-user:

Orthopedic Clinics
Over the Counter (OTC)
Hospitals
DME Dealers
Others

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia and the Pacific
East Asia
Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Automated Cell Culture Systems Market Set for Remarkable Growth, Projected to Reach USD 20.87 Billion by 2030 at a 8.4% of CAGR

The global automated cell culture systems market is experiencing rapid expansion, driven by significant advancements in stem cell research, drug development, and innovation investments. According to recent data, the market is poised to grow at an impressive compound annual growth rate (CAGR) of 8.4%, increasing from a valuation of USD 10.91 billion in 2022 to USD 20.87 billion by 2030.

Automated cell culture systems currently hold a substantial 44.5% share of the global cell culture market, reflecting their pivotal role in advancing biological research and pharmaceutical development. The expansion of this market is being driven by several key factors, including rising investment in stem cell research and development, recent drug breakthroughs, and increased funding towards the development of innovative cell culture technologies.

The surge in demand for automated systems is attributed to their ability to enhance efficiency, reproducibility, and scalability in cell culture processes. These advancements are critical for accelerating research and development efforts, particularly in the fields of drug discovery and regenerative medicine.

Besides, 3D cell cultures, which were cumbersome and costly earlier, have become feasible, owing to advent of spheroids. Also, they imitate tumors better due to hypoxic core and presence of nutrient gradient.

Researchers in the US and Germany have come up with a protocol to grow 3D cultures of generally used cancer cells to facilitate drug screenings. These factors will continue to put North America and Europe at the top pedestal in the automated cell culture systems market.

Further, the requirement of cell lines for devising vaccines against COVID-19 infection will augur well for the automated cell culture market despite the pandemic-induced economic downturn.

Automated Cell Culture Systems Market Outlook & Key Findings

Automated cell culture systems market is expected to witness a CAGR of 8% through 2030
Growing applications of cell lines in drug discovery to be a key growth driver
Consumables hold more than 60% of market value owing to ever-increasing research in stem cells and oncology
North America to capture more than 40% of market value and is expected to witness a CAGR of 6% through 2030
Biotech companies to remain prominent end users throughout the forecast period

Key Takeaways from the Automated Cell Culture Systems Market

Consumables are expected to reach US$ 11 Bn by 2030
Academic institutes are expected to take greater interest in research related to cell culture over the forecast period due to increased government funding in developed countries
North America and Europe collectively accounted for more than 60% of market share in 2019
Infinite cell line cultures held close to 75% of market share in 2019

“Advancements in technology, coupled with large-scale applications in cell-based drug delivery and drug discovery, are projected to drive the global automated cell culture systems market” – says the FMI analyst.

A Old Full Report Analysis Click Here

Key Segments of Automated Cell Culture Systems Industry Survey

Automated Cell Culture Systems Market by Product:

Automated Cell Culture Storage Equipment
Automated Cell Culture Vessels
Bioreactors
Consumables

Automated Cell Culture Systems Market by Cell Culture:

Finite Cell Line Cultures
Infinite Cell Line Cultures

Automated Cell Culture Systems Market by Application:

Drug Development
Stem Cell Research
Regenerative Medicine
Cancer Research

Automated Cell Culture Systems Market by End User:

Biotech Companies
Research Organizations
Academic Institutes

Automated Cell Culture Systems Market by Region:

North America Automated Cell Culture Systems Market
Latin America Automated Cell Culture Systems Market
Europe Automated Cell Culture Systems Market
East Asia Automated Cell Culture Systems Market
South Asia & Pacific Automated Cell Culture Systems Market
Middle East & Africa (MEA) Automated Cell Culture Systems Market

Automated Cell Culture Systems Market: Competitive Insights

The global automated cell culture systems market is set to expand its scope in the forecast period, stimulated by increasing drug discovery research and diverse applications of cell lines in research purposes. Furthermore, automated cell culture systems are used for experiments in drug discovery research and in cell banking process. In addition, cost effectiveness and rise in alternative methods for traditional cell culture production is augmenting the adoption of automated cell culture systems.

Key market players covered in the market include Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Tecan Trading AG, Hamilton Medical AG., Biospherix and Promocell GmbH. Key players integrate their positions through acquisitions, mergers and new product launches.

Want more insights?

The study provides compelling insights on automated cell culture systems market on basis of product type (automated cell culture storage equipment, automated cell culture vessels, bioreactors and consumables), cell culture type (finite cell line cultures, infinite cell line cultures), application (drug development, stem cell research, regenerative medicine and cancer research) and end user (biotech companies, research organizations, academic institutes), and across seven major regions.

Author by

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Oligonucleotide APIs Market Poised for Robust Growth USD 4.84 Billion with a Projected CAGR of 5.60%

The global oligonucleotide active pharmaceutical ingredients (APIs) market is set for significant expansion over the next decade, driven by the increasing demand for new drug classes. According to recent projections, the market is anticipated to grow at a robust compound annual growth rate (CAGR) of 5.60% from 2024 to 2034.

Starting from a valuation of USD 2.81 billion in 2024, the oligonucleotide API market is expected to reach an estimated USD 4.84 billion by the end of 2034. This growth reflects the rising need for advanced therapeutic solutions and the ongoing innovations in drug development that are fueling the demand for oligonucleotide APIs.

This anticipated growth is fueled by the growing need for advanced therapeutic options and the development of innovative drug classes that utilize oligonucleotide APIs. The surge in research and development activities, coupled with the rising prevalence of genetic and chronic diseases, is expected to drive demand for these specialized APIs.

The market’s expansion underscores the increasing importance of oligonucleotide APIs in drug development and their pivotal role in advancing personalized medicine. As the industry evolves, stakeholders, pharmaceutical companies, and investors are presented with significant opportunities in this dynamic sector.

Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst COVID-19) are acting as restraints.

Key Takeaways from Global Oligonucleotide API Industry Study

Antisense oligonucleotide APIs are anticipated to reach US$ 4 Bn by 2030.
North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
Increase in the use of antisense oligonucleotide APIs (especially post-approval from the US FDA in 2016) to boost the market in the forecast period

“Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the Global Oligonucleotide API Industry,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.).

New Product Launches: Key Indicators to Global Oligonucleotide API Industry

FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.

For instance –

In March 2020, Dynavax entered into a collaboration with Clover Biopharmaceuticals to develop a vaccine candidate to combat COVID-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.

Gene Therapy and Oligonucleotide APIs

Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.

Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals to sell the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.

A Old Full Report Analysis Click Here

Key Segments of Oligonucleotide API Industry Survey:

Global Oligonucleotide API Industry by API:

Antisense Oligonucleotides APIs
Short Interfering RNA (siRNA) APIs
Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
MiRNA APIs
Aptamers APIs
CpG Oligonucleotides APIs
Others (ON Conjugates (NP), ShRNA, etc.)

Global Oligonucleotide API Industry by Marketing Status:

Marketed
Clinical Trials (Clinical Phases)

Global Oligonucleotide API Industry by End User:

Contract Manufacturing Organizations (CMOs)
Pharmaceutical Companies
Biopharmaceutical Companies
Contract Development & Manufacturing Organizations (CDMOs)

Global Oligonucleotide API Industry by Region:

North America Oligonucleotide API Market
Latin America Oligonucleotide API Market
Europe Oligonucleotide API Market
East Asia Oligonucleotide API Market
South Asia & Pacific Oligonucleotide API Market
Middle East & Africa (MEA) Oligonucleotide API Market

Key Companies Profiled:

Jazz Pharmaceuticals, Inc.
Sarepta Therapeutics
Biogen
Dynavax Technologies
Akcea Therapeutics.
Alnylam Pharmaceuticals, Inc.

Author

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Injectable Benzodiazepines Market Projected to Grow to reach USD 356 Million by 2032 at a 2.7% of CAGR

The Global Injectable Benzodiazepine Industry are predicted to reach USD 274 million by the end of 2022. Sales of injectable benzodiazepines are predicted to reach USD 356 million by 2032’s end. From 2022 to 2032, the injectable benzodiazepines market is anticipated to expand at a 2.7% CAGR.

Global Injectable Benzodiazepine Industry sales are set to reach USD 260 million in 2020, as COVID-19 panic and uncertainty have set in, even among populations with no previous history of mental illnesses, according to a new study by Future Market Insights (FMI). The market research firm estimates the market to grow at 2.7% CAGR through 2030.

Although COVID-19 will create a short-term spike, in the long run, the market is likely to be driven by increasing demand for generic drugs. Growing acceptance of injectables as a route of administration is also likely to drive growth.

Key Takeaways of Global Injectable Benzodiazepine Industry Study

Lorazepam injectable benzodiazepine accounted for the highest share in the injectable benzodiazepine market in 2019
Seizures and anxiety are among the leading ailments where injectable benzodiazepines are administered
North America and Europe are expected to hold a noteworthy revenue share of about 60% in the Global Injectable Benzodiazepine Industry in 2020

Low-cost manufacturing and large patient pools in Asian countries are expected to be a key growth driver in the forecast period

“Growing incidences of seizures and anxiety followed by demand for generics to boost the Global Injectable Benzodiazepine Industry,” says an FMI Analyst.

Research Collaborations: Key to Sustenance

The market players are emphasizing expanding their manufacturing facilities with the introduction of cost-effective and generic drugs and also venturing into strategic partnerships.

In Jan 2020, Hospital Sales Force from Xellia signed an agreement with Eton to promote Biorphen in institutions that prefer having ready-to-use injectable formulations
In Oct 2019, KemPharm’s APADAZ (to treat ADHD) got licensed to KVK-Tech, Inc. to make its generic AG-APADAZ available all across the US
In Dec 2018, Hikma Pharmaceuticals came up with clobazam oral suspension as well as tablets, the generic equivalent to “Onfi” (marketed by H. Lundbeck A/S)

What else is in the report?

Future market insights offer a unique perspective and actionable insights on the Global Injectable Benzodiazepine Industry in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on drug class (diazepam, lorazepam, and midazolam), by the time of action (short-acting long-acting), by indication (agitation & aggression, anxiety, alcohol withdrawal, muscle spasm, seizures, tetanus, sedation, anesthesia insomnia, and status epilepticus), by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) in seven key regions.

A Old Full Report Analysis Click Here

Key Segments of the Global Injectable Benzodiazepine Industry

FMI’s study on the injectable benzodiazepines market offers information divided into three important segments— drug class, indication, time of action, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Class

Diazepam
Lorazepam
Midazolam

Time of Action

Short Acting
Long Acting

Indication

Agitation & Aggression
Anxiety
Alcohol Withdrawal
Muscle Spasm
Seizures
Tetanus
Sedation
Anesthesia
Insomnia
Status Epilepticus

Distribution Channel

Hospital
Ambulatory Surgical centers
Diagnostics Centers

Author

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Guidewires Market Poised for Strong Growth, Projected to Reach US$ 5.9 Billion by 2030 at a 6.1% of CAGR

The global guidewires market is on track for substantial growth, according to recent analysis. The market is estimated to have reached a value of approximately USD 3.7 billion in 2022 and is forecasted to experience a robust compound annual growth rate (CAGR) of 6.1% from 2022 to 2030.

This anticipated growth reflects a rising demand for guidewires, driven by advancements in medical technology, an increase in minimally invasive procedures, and a growing prevalence of chronic diseases that require advanced diagnostic and therapeutic interventions. The expansion of healthcare infrastructure and innovations in guidewire design and materials are also contributing to the market’s positive outlook.

The guidewires market is positioned to benefit from ongoing improvements in medical devices and techniques, making it a key area of interest for stakeholders, investors, and industry professionals.

The WHO Global NCD Action Plan 2015-2021 does follow on with recognition of primary role as well as responsibility of various governments regarding responding positively to challenge posed by NCDs and international co-operation for supporting national efforts.

A part of their action plan is bringing down all the NCDs listed above by at least 30% and render 80% availability of basic technologies/medications.

These include provision of guidewires to facilitate minimally-invasive surgical procedures at affordable rates in ambulatory centres. These factors have been collectively driving the guidewires market till date and will continue to do so in the forecast period as well.

Plus, US FDA has come up with guidelines regarding upgradation of guidewires to ensure faster and more efficient procedures. This is another factor giving impetus to the market. This upgradation is likely to happen through inorganic as well as organic mode of expansion.

Again, as per FMI, the global guidewires market is slated to value US$ 3.3 Bn in 2022 and expected to witness a substantial CAGR of over 6.0% between 2022 and 2030.

Key Takeaways of Guidewires Market Study

The global guidewires market, in the year 2021, was dominated by interventional guidewires as they continue to be the first choice with regards to minimally-invasive surgical procedures
As far as applications are concerned, peripheral and coronary guidewires collectively account for around 65% of revenue share
By material, stainless steel, due to superior torque and ductility, is expected to be the highest revenue generator in the forecast period.
North America is expected to be the most lucrative region and expected to generate around 40% of the overall revenue in 2022 and this trend is expected to continue during the forecast period.

“Technological advancements such as the development of multifunctional and low-cost guidewires are expected to provide an innovative paradigm shift to market players.” Says the FMI Analyst.

New Product Launches – The Win-Win Strategy for Market Players

The market players are focusing on launching advanced products for supporting clinicians with respect to interventional or diagnostic procedures. For instance – Olympus Corporation, in May 2021, tabled RevoWave endoscopic guidewire in the U.S. for performing balloon dilation, biliary endoscopy, and stent placement.

On the similar grounds, Abbott’s Frontline Workhorse guidewires are making ways for most interventional devices.

What else is in the report?

Future Market Insights offers actionable insights and unique perspective on guidewires market in its latest study, presenting historical demand assessment from 2015 – 2021 and projections from 2022–2030 based on product type (interventional guidewires and diagnostic guidewires), by application (coronary guidewires, peripheral guidewires, urology guidewires, radiology guidewires, neurovascular guidewires, gastroenterology guidewires and others) by material type (Nitinol guidewires, PTFE guidewires, stainless steel guidewires and hybrid guidewires) by tip shape (J tip, angled tip and straight tip) by end-user (hospitals, ambulatory surgical centres, cardiac catheterization laboratories and speciality clinics) in seven key regions.

A Old Full Report Analysis Click Here

Key Market Segments Covered In Guidewires Industry ResearchBy Product :

Interventional Guidewires
- Hydrophilic Guidewires
- Hydrophobic Guidewires
Diagnostic Guidewires
- Hydrophilic Guidewires
- Hydrophobic Guidewires

By Application :

Coronary Guidewires
Peripheral Guidewires
Urology Guidewires
Radiology Guidewires
Neurovascular Guidewires
Gastroenterology Guidewires
Others

By Material Type :

Nitinol Guidewires
PTFE Guidewires
Stainless Steel Guidewires
Hybrid Guidewires

By Tip Shape :

J Tip
Angled Tip
Straight Tip

By End User :

Hospitals
Ambulatory Surgical Centers
Cardiac Catheterization Laboratories
Specialty Clinics

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Swab and Viral Transport Medium Market Set to Surge, Projected to Reach USD 15.60 Billion by 2033 at a 5.8% of CAGR

According to the latest market attractiveness analysis by Future Market Insights (FMI), the global swab and viral transport medium market is poised for significant growth. Estimated to reach approximately USD 8.86 billion by the end of 2023, the market is projected to expand at a compound annual growth rate (CAGR) of 5.8% over the next decade. By 2033, the market is expected to surpass a valuation of USD 15.60 billion.

This robust growth is driven by increased demand for reliable diagnostic tools and advancements in viral transport technologies. The expansion reflects a rising need for effective solutions in medical diagnostics and testing, positioning the market for continued success and innovation in the years to come.

This significant growth trajectory underscores the increasing demand for swab and viral transport mediums, driven by their crucial role in diagnostic testing and disease management. The rise in global health initiatives, heightened awareness of infectious diseases, and advancements in diagnostic technologies are key factors contributing to this market expansion.

The analysis highlights the evolving needs of healthcare providers and the growing emphasis on accurate and efficient testing processes. As the market evolves, stakeholders and industry players are presented with substantial opportunities for growth and innovation.

Companies in the swab and viral transport medium business are producing inventive kits with vials, double-ended flocked swabs, medications, and other items that avoid bacterial or fungal contamination. They are concentrating on a better solution formulation to stop the growth of bacterial and fungal flora. The market is expanding owing to new viral transport medium solutions.

An additional element fueling the market expansion is the rise in the number of novel viruses that have the potential to infect humans and cause a variety of illnesses. According to an article in Nature from 2021, certain respiratory viruses are resurfacing in unexpected ways as pandemic limitations loosen. Infections with the respiratory syncytial virus (RSV), which accounts for 5% of all pediatric fatalities globally, began to rise in April 2021. As a result of the increased need for specimen collection kits and diagnosis, the prevalence of additional infectious illnesses is predicted to propel market expansion.

Manufacturers are creating viral transport mediums for influenza diagnostics as the flu season gets underway. Healthcare in western nations is extremely concerned about influenza-related morbidity and death. To provide swabs and viral transport mediums, manufacturers are expanding their research and development capabilities. Manufacturers are also starting to recognize the advantages of online pharmacies over hospitals and retail pharmacies. To increase their revenue sources, they are working with established e-Commerce companies.

Owing to its highly developed medical infrastructure and high frequency of infectious illnesses, North America is predicted to dominate the global market during the forecast period. During the pandemic, North America saw a spike in laboratory testing, which fueled the market expansion. The market is also growing significantly due to the existence of biopharma businesses, a large number of labs, and research studies on viral infection.

Key Takeaways

The market in the United Kingdom is anticipated to rise, exhibiting a CAGR of 9%through 2033.
The United States is expected to develop at a1%CAGR during the forecast period.
With a CAGR of 0%over the forecast period, Canada is predicted to develop promptly in the market.
In China, the market is expected to proliferate, registering a CAGR of 7%over the forecast period.
Germany is estimated to grow decently registering a CAGR of 7% until 2033.

Competitive Landscape

Top players operating in the swab and viral transport medium market are McKesson Corporation, Cardinal Health Inc., Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Quidel Corporation, COPAN Diagnostics Inc., VIRCELL S.L., Deltalab, Titan Biotech Ltd., Medical Wire & Equipment, and others.

These market players are always inventing and creating new products to suit the various requirements of diagnostic laboratories and research institutions. They are enhancing the design and components used in swabs to enhance their collection efficacy. They are also developing transport mediums that can hold viral specimens for extended periods without compromising their vitality. Additionally, to improve the stability and accuracy of diagnostic samples, they are also combining advanced technologies.

Recent Developments

In June 2022, the start of long-distance drone deliveries in North Carolina was announced by Zipline and Cardinal Health.
In May 2020, in several pharmacies across the United States, Health Mart® pharmacies announced that they would provide free COVID-19 test collection. Health Mart is dedicated to creating cutting-edge public and private collaborations as a member of the McKesson Corporation to assist address the COVID-19 epidemic.

Other Key Players Operating in the Swab and Viral Transport Market

Thermo Fisher Scientific Inc.,
Quidel Corporation,
COPAN Diagnostics Inc.,
VIRCELL S.L., Deltalab,
Titan Biotech Ltd.,
Medical Wire & Equipment

Swab and Viral Transport Medium Market by Category

By Product:

Viral Transport Medium
- Tissue Culture Medium
- Glycerol Transport Medium
Virus Swabs
- Nasopharyngeal Swabs
- Deep Nasal Swabs
- Combined Nasal & Throat Swabs
- Culture Swabs
- Vaginal Swabs

By Application:

Influenza
Respiratory syncytial virus
Mumps Virus
Adenovirus
Rhinovirus
Herpes Simplex Virus
Varicella-Zoster Virus
Other Indication

By End User:

Hospitals & ASCs
Specialty Clinics
Diagnostic Laboratories
Others

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Eye Infections Treatment Market Set to Reach USD 9.9 Billion by 2030 at a 3.8% of CAGR

The global Eye Infections Treatment Market is experiencing notable growth, with worldwide revenue estimated at USD 7.3 billion in 2022. According to recent forecasts, the market is projected to advance at a compound annual growth rate (CAGR) of 3.8% from 2022 to 2030. This robust growth trajectory is expected to drive the market’s value to approximately USD 9.9 billion by the end of the decade.

The increasing prevalence of eye infections and advancements in treatment options are key factors contributing to this market expansion. As the demand for effective and innovative treatments continues to rise, the eye infections treatment market is poised for continued progress and significant growth over the coming years.

The projected growth reflects a rising demand for advanced treatments and therapies for eye infections, driven by increasing incidences of ocular diseases, advancements in medical technologies, and growing awareness about eye health. The market expansion is supported by ongoing research and development efforts aimed at enhancing the effectiveness and accessibility of treatments.

This upward trajectory highlights the importance of continued innovation and investment in the eye infections treatment sector, offering significant opportunities for healthcare providers, pharmaceutical companies, and investors alike.

Key Takeaways of Eye Infection Treatment Market Study

Antibiotics would contribute over 55% of revenue share in the eye infection treatment market owing to their use in treating primary eye infections and post-surgical eye infections.
Eye drop sales capture over 60% market share in the eye infection treatment market.
Conjunctivitis would account for a third of eye infection treatment demand through 2030.
Bacterial infections continue to account for over 3/5^th market share.
Hospitals and retail pharmacies collectively generate over 70% of total returns to shareholders.
The increasing rate of eye surgeries and rising usage of contact lenses continue to push the North American market. European market would be upheld by the expanding geriatric pool.

Demand for eye infection treatment will continue to receive a strong impetus from increasing awareness about different eye infection types and availability of treatment, further complemented by technological advancements on ophthalmology.

Development and Licensing Deals with Multiple Commercialization Partners

Technology developers are laying greater emphasis on developing of novel ophthalmic formulation technologies and engaging with commercialization partners with licensing-out proprietary ophthalmic technologies.

For instance, Nicox S.A. has licensed out ZERVIATE (cetirizine ophthalmic solution) 0.24% to Eyevance Pharmaceuticals LLC for commercialization of ZERVIATE in the US. ZERVIATE is the first topical ocular formulation of antihistamine cetirizine approved for treatment of ocular itching associated with allergic conjunctivitis. In addition, Ocumension Therapeutics is responsible for all development and commercialization activities in Chinese market for ZERVIATE.

Demand for Eye Infection Drugs to Slump Amidst COVID-19 Pandemic

The coronavirus (COVID-19) pandemic has resulted in widened gap between supply and demand of eye infection treatments. As such, it has significantly reduced ocular surgery rate for short-term basis and, in turn, post-operative eye infections.

According to World Health Organization (WHO), national healthcare resources redirection and utilization to contain COVID-19 pandemic is expected to delay and reschedule the treatment of non-critical healthcare conditions for brief period, including eye care services, and ocular surgeries.

Know More About FMI’s Global Eye Infections Treatment Industry Study

Eye infection treatment market, a new study from Future Market Insights, opines on eye infections treatment from 2015 – 2021 and presents demand projections from 2022 – 2030 on the basis of; drug class (antibiotics, antivirals, antifungals, antihistamines, corticosteroids, and glucocorticoids), dosage form (tablet, capsule, ophthalmic ointment, and eye drops), indication (conjunctivitis, keratitis, endophthalmitis, blepharitis, stye or sty (hordeolum), uveitis, cellulitis, and ocular herpes), causative agent (virus, bacteria, fungus, and allergens) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and drug stores) across seven prominent regions.

A Old Full Report Analysis Click Here

Key Segments of Global Eye Infections Treatment Industry Survey By Drug Class:

Antibiotics
- Sulfonamides
- Macrolides
- Erythromycin
- Chloramphenicol
- Aminoglycosides
- Fluoroquinolones
- Vancomycin
- Tetracyclines
Antivirals
- Thymidine-Based Nucleoside Analogues (Trifluridine)
- Thymidine Phosphorylase Inhibitors (Trifluridine)
- Acyclic Nucleoside Analogue of 2’Deoxyguanasine (Ganciclovir)
- Acyclic Guanine Nucleoside Analog (Acyclovir)
- Others
Antifungals
- Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
- Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
- Pyrimidines
- Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
- Others
Antihistamines
Corticosteroids
Glucocorticoids

By Dosage Form:

Eye Infections Treatment Tablets
Eye Infections Treatment Capsules
Eye Infections Treatment Ophthalmic Ointments
Eye Infections Treatment Eye Drops
Others

By Indication:

Eye Infections Treatment for Conjunctivitis
Eye Infections Treatment for Keratitis
Eye Infections Treatment for Endophthalmitis
Eye Infections Treatment for Blepharitis
Eye Infections Treatment for Stye or Sty (Hordeolum)
Eye Infections Treatment for Uveitis
Eye Infections Treatment for Cellulitis
Eye Infections Treatment for Ocular Herpes

By Causative Agent:

Virus
Bacteria
Fungus
Allergens

By Distribution Channels:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Medical Ventilators Market Set for Robust Growth, Projected to Exceed USD 4 Billion by 2033 at a 9.1% of CAGR

According to recent market research by Future Market Insights (FMI), the global medical ventilators market is poised for significant expansion, with an anticipated market value of USD 1.7 billion in 2023.

The market is projected to grow at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2033, reflecting the increasing demand for advanced respiratory support technologies. By 2033, the medical ventilators market is expected to surpass USD 4 billion, driven by advancements in medical technology and heightened awareness of respiratory health needs.

The impact of the COVID-19 pandemic has further accelerated market growth. As a result of viral infections, many patients have required ventilator support. In response, governments around the world have made significant investments in medical ventilator procurement. For instance, in April 2020, the United States government entered into a US$ 1.1 billion contract with General Health and Philips to bolster ventilator supplies. Additionally, in the same month, the United Kingdom secured 300 new ventilators from China.

The market has been witnessing technological advancements of late. The manufacturers have been enhancing the ventilators with sensors. This would ensure almost no interference from human beings. Thus, the human resource can be streamlined and directed to other important areas of the business.

The surging geriatric population across the globe is also expected to surge the sales of medical ventilators. This age group is prone to almost any kind of ailment, especially respiratory issues and cancer cases.

Thus, the FMI analysts believe that, ‘rapid urbanisation, COVID-19 pandemic, technological advancements, and a lot of other factors are expected to propel the medical ventilators market growth during the forecast period.’

Medical Ventilators Market Key Takeaways:

The market is expected to record a growth rate of 9.1%.
In 2023, the market valuation is expected to be at US$ 1.7 billion.
By 2033, the market value is expected to surpass US$ 4 billion.
As per the regional analysis, North America is expected to be the largest market.
The United States market is expected to grow at 6.8%.
The United Kingdom market is projected to advance at 5.8%.
China’s market is anticipated to surge by 14.7%.
Japan’s market is expected to advance at 9.1%.
The South Korean market is anticipated to grow at 8%.
Based on product type, critical care ventilators are expected to be the leading segment and may surge at 8.6%.
Based on application, invasive ventilators are projected to be the dominant segment and are expected to grow at 7.5%.
Based on the end user, the hospital segment is expected to be the leading segment.

Medical Ventilators Market Competitive Landscape

The key players operating in the medical ventilators market are focusing on product innovation. On that basis, they are looking to integrate their products with the latest microprocessors. There are also huge investments being made in Research and Development, to create the best quality ventilators. The manufacturers are also investing in tactical mergers and acquisitions, to expand their market share. To achieve sustainable goals, the manufacturers are also looking to cut down greenhouse emissions and make use of eco-friendly facilities. To make new strategic moves, the key players are also roping in some of the most astute minds who have been a part of this niche for decades.

Top players in the market:

Cardinal Health
Becton Dickinson and Company
GE Healthcare

Key developments in the medical ventilators Industry:

In October 2022, new research conducted by Cardinal Health highlights rheumatologist’s increasing confidence in biosimilars.
In January 2023, Michelle Quinn was named as the acting General Counsel for Becton, Dickinson, and Company.

Medical Ventilators Market Segmentation

By Product:

Critical Care Ventilators
Transport Ventilators

By Application:

Invasive Ventilators
Non-invasive Ventilators

By End User:

Hospitals
Ambulatory Surgical Centers
Long-Term Care Centers
Home Care Settings

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Astaxanthin Market Projected to Achieve USD 665.0 Million by 2034 Driven by Growing Food and Cosmetic Industry Needs | FMI

According to Future Market Insights (FMI), global astaxanthin sales are estimated to be worth US$ 273.2 million in 2024. The market is expected to reach US$ 665.0 million by 2034. It is projected to surge at a CAGR of 9.3% in the forecast period 2024 to 2034.

Astaxanthin’s increasing demand is driven by its use in aquaculture, animal feed, nutraceuticals, cosmetics, pharmaceuticals, and food & beverages industries. It is widely used as a food ingredient for prawns and fish to enhance coloration and commercial value.

Astaxanthin benefits aquatic animals by increasing stress tolerance, performance, immune-related gene expressions, reproductive capacity, survival, and disease resistance. The market is expected to rise due to the consistent demand from the food industry, where astaxanthin is used as a food additive due to its health benefits, such as anti-inflammatory effects and prevention of cardiovascular diseases. Studies have shown that astaxanthin is set to prevent photo-aging, improve sleep, minimize obesity, protect the vocal cord, combat depression, and increase sperm motility.

Natural alternatives are gaining traction due to a number of factors, including greater awareness of the harmful effects of chemicals and expanding usage of synthetic ingredients in topical & culinary items. As a result, leading companies are implementing tactics, including the introduction of new products and alliances with key manufacturers in several sectors to boost the market share of natural astaxanthin-based products.

Key Takeaways from the Astaxanthin Market Report:

The global astaxanthin market is expected to reach a valuation of US$ 665.0 million by 2034.
Japan is projected to hold a dominant value share of 3.5% by 2034.
The United States astaxanthin market is projected to reach a valuation of US$ 177.6 million by 2034.
India’s astaxanthin market is projected to reach US$ 43.0 million by 2034.
Germany is set to hold a dominant value share of 4.1% by 2034.

“The astaxanthin market is experiencing innovation as dietary lutein becomes a potential substitute in the market. Leading companies are incorporating lutein-rich sources into formulations, highlighting a trend toward diversification. They are also exploring alternative natural compounds.” – says a lead analyst at Future Market Insights (FMI).

Extensive Market Research: Complete Report and Findings

Competitive Landscape

BASF SE, Divi’s Laboratories Ltd., Cyanotech Corporation, DSM N.V., Parry Nutraceuticals, and JXTG Nippon Oil & Energy Corporation are key astaxanthin manufacturers listed in the report. Leading companies are concentrating on broadening their portfolios by launching new products. They also use strategies such as advertisements, partnerships, acquisitions, agreements, and mergers to stay relevant in the market.

For instance,

In 2020, BGG declared two key extensions of its farm capacity of astaxanthin as the company has seen a surge in its astaxanthin sales lately.

Key Companies Profiled

BASF SE
Divi’s Laboratories Ltd.
Cyanotech Corporation
DSM N.V
Parry Nutraceuticals
JXTG Nippon Oil & Energy Corporation
Fuji Chemical Industries Co., Ltd.
Kunming Biogenic Co., Ltd.
Valensa International Global
Kailu Ever Brilliance Biotechnology Co. Ltd.
Algalif Iceland Ehf
Zhejiang NHU Co., Ltd.
Atacama Bio Natural Products S.A., Inc.
AstaReal Inc
Fenchem Biotek Ltd.
Igene Biotechnology, Inc.
BGG (Beijing Gingko Group)
Cardax, Inc.
Algatechnologies Ltd.
Algaecan Biotech Ltd.
Otsuka Pharmaceutical Co., Ltd.
Yunnan Alphy Biotech Co., Ltd.
INNOBIO Corporation Limited.
Sinoway Industrial Co., Ltd.
KDI Ingredients

Get More Valuable Insights

Future Market Insights (FMI), in its new offering, provides an unbiased analysis of the global astaxanthin market, presenting historical demand data (2019 to 2023) and forecast statistics for the period from 2024 to 2034.

The study incorporates compelling insights on the astaxanthin market based on species type (haematococcus pluvialis, chlorococcum, chlorella zofingiensis), production technology (chemical synthesis, natural extraction), form (tablets, soft gel capsules, powder, liquid), grade (>=98%, 95%-97%, <=94%), application (aquaculture, dietary supplements, food & beverages, personal care & cosmetics, pet food), and region.

About the Food & Beverage Division at Future Market Insights (FMI)

Expert analysis, actionable insights, and strategic recommendations – the Food & Beverage team at Future Market Insights (FMI) helps clients from all over the globe with their unique business intelligence needs. With a repertoire of over 1,000 reports and 1 million+ data points, the team has analyzed the food & beverage industry lucidly in 50+ countries for over a decade. The team provides end-to-end research and consulting services; reach out to explore how we can help.

About Future Market Insights (FMI)

Contact FMI:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Citrus Pulp Market Set for Expansion: Expected to Reach USD 287.2 Million by 2033 with 5.9% CAGR

The citrus pulp market (Markt für Zitrusfruchtmark) refers to the global trade and consumption of citrus pulp, which is a byproduct of the citrus fruit processing industry. Citrus pulp is obtained from the remnants of oranges, lemons, grapefruits, and other citrus fruits after juice extraction. It is rich in fiber, pectin, and other nutrients, making it a valuable ingredient in various industries.

The demand for citrus pulp has been steadily increasing in recent years due to its wide range of applications. In the animal feed industry, citrus pulp is used as a feed ingredient for livestock, such as cattle, poultry, and swine. It provides essential nutrients, improves digestion, and enhances animal health. Additionally, citrus pulp helps in reducing the dependence on traditional feed ingredients like corn and soybean, making it a sustainable alternative.

The citrus pulp market is anticipated to be worth US$ 180.97 million in 2023 and US$ 287.2 million by 2033. Citrus pulp demand is anticipated to maintain a constant CAGR of 5.9%.

The demand for natural and healthy ingredients is increasing as consumers become more health conscious. Citrus pulp feed is a natural and organic ingredient that contains high levels of fiber, making it a popular choice for health-conscious consumers. In addition, it is low in fat and calories, which makes it an attractive ingredient for weight management products. As the demand for natural and healthy ingredients continues to rise, the citrus pulp market is expected to grow.

Sustainability is becoming a key concern for companies and consumers alike. Citrus pulp feed is a sustainable ingredient that can be used in a variety of applications, including animal feed, food and beverage products, and packaging. It is a by-product of the citrus juice industry, which helps to reduce waste and promote sustainability. As companies and consumers become more conscious of sustainability, the demand for citrus pulp is expected to increase.

Demand for Citrus Fiber Is Growing as Many People Try to Buy Products Free from Harmful Ingredients.

Since scientists have discovered citrus fibers’ health benefits, manufacturers have been adding them to several products to boost sales of citrus pulp. Citrus fiber is used in a wide variety of foods and beverages, including to fruit juices and yoghurts, salad dressings, condiments, sauces, baked goods, meats, and soups. Researchers have found that citrus fiber has numerous health benefits, including the prevention of cancer, improvement of heart health, digestion, stress relief, and skin tone.

Polyphenols, vitamin C, and flavonoids are just few of the bioactive compounds found in citrus fiber that contribute to its health benefits. As clean-label foods and drinks become the norm, consumers are looking to our clients for cutting-edge solutions to meet their needs. Companies that sell citrus fiber tout not only its health advantages, but also its potential to replace eggs and oil, clean label, and its contribution to sustainability by making productive use of post-processed citrus that would otherwise be thrown away.

The rising demand for naturally derived cosmetics is prompting several players in the citrus fiber market to emphasize their continued investment in ingredient innovation for broad cosmetic and personal care applications. Furthermore, the rising interest in natural remedies is driving up demand for citrus ingredients in all sorts of cosmetics. Citrus fibers, which are essential for enhancing the body’s metabolism and digestion, have been seeing a rise in popularity as consumers become more concerned about the safety of the food they eat. Citrus fiber’s inclusion in a wide variety of products across sectors reflects the growing clean label movement’s emphasis on the importance of using ingredients with few or no artificial ingredients.

Key Takeaways:

The availability and demand for citrus pulp around the year, owing to the presence of several citrus fruit juice production facilities, is aiding the long-term prospects of the industry.
Europe market holds a predominant position, accounting for over 30% of the global market share, driven by demand from consumers in the United Kingdom, Germany, and France.
The demand for orange-based citrus pulp is expected to account for a significant market share through the end of the forecast period.
The market is facing challenges related to contaminants and counterfeit products, and fluctuations in yield due to environmental factors.
The demand for citrus pulp in the bakery products segment is estimated to remain the prominent in the near future, driven by growing applications in confitures and fresh fruit pastries.
Citrus pulp feed is used in various end-use applications, including bakery, sauces and seasonings, meat and egg replacement, personal care, and pharmaceutical offerings, among others.
The growing demand for convenience foods is expected to bolster fast growth in the snacks and meals segment.

Competitive Landscape:

The citrus pulp market is highly competitive and fragmented, with several key players vying for market share. Some of the leading companies in the market include:

Fiberstar, Inc.
Cargill, Inc.
Commodity Specialists Company
Agrifiber Products, Inc.
DuPont de Nemours, Inc.
Ingredion, Inc.
Tereos Group
CP Kelco U.S., Inc.
Florida Food Products, LLC
Ceamsa

The market is characterized by intense rivalry among players, with strategies such as product innovation, mergers and acquisitions, and strategic partnerships being employed to gain a competitive edge. Moreover, market players are focusing to expand their production capacities to cater to the growing demand for citrus pulp from various end-use industries.

The market is also witnessing the entry of new players, which is further intensifying the competition. This is expected to drive innovation and result in the development of new and advanced products in the market. Overall, the competitive landscape of the citrus pulp market is expected to remain highly dynamic and competitive in the coming years.

In-Depth Market Analysis: A Complete Report

Key Segments

Nature:

Organic
Conventional

Source:

Oranges
Tangerines/Mandarins
Grapefruit
Lemon and Lime

End Use:

Bakery
Desserts and Ice-Creams
Sauces and Seasonings
Meat and Egg Replacement
Beverages, Flavorings, and Coatings
Snacks and Meals
Personal Care
Pharmaceuticals
Others

Distribution Channel:

Supermarkets/Hypermarkets
Convenience Stores
Departmental Stores
Specialty Stores
Pharmacy/Drug Stores
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube